Basis: Four-quarter operating cash flow / FMP quote market capitalization × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The operating cash flow yield is N/A as of 2026-10-06T16:57:31.671Z.
Calculation as of: 2026-10-06T16:57:31.671Z.
Quote observation: 2026-10-06T16:55:18.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 619c5482a9d59cec4bb20d2c4447c35828cdfaa1e6076b938dd954a9c5cde0ad
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
OPERATING CASH FLOW YIELD
N/A
Mineralys Therapeutics, Inc.
Market Cap
$1.97B
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.98B
Operating Cash Flow Yield
7.94%
TTM Avg
7.39%
3Y Avg
3.49%
5Y Avg
2.93%
Market Cap
$1.96B
Operating Cash Flow Yield
0.47%
TTM Avg
0.48%
3Y Avg
0.57%
5Y Avg
0.57%
Market Cap
$2.02B
Operating Cash Flow Yield
8.62%
TTM Avg
6.71%
3Y Avg
5.45%
5Y Avg
5.45%
Market Cap
$1.91B
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$2.04B
Operating Cash Flow Yield
12.11%
TTM Avg
10.56%
3Y Avg
8.92%
5Y Avg
5.93%
Market Cap
$2.04B
Operating Cash Flow Yield
17.62%
TTM Avg
10.04%
3Y Avg
8.73%
5Y Avg
8.73%
Market Cap
$1.90B
Operating Cash Flow Yield
N/A
TTM Avg
2.90%
3Y Avg
2.90%
5Y Avg
2.90%
Market Cap
$1.90B
Operating Cash Flow Yield
N/A
TTM Avg
3.33%
3Y Avg
3.33%
5Y Avg
3.33%
| NAME | MARKET CAP | OPERATING CASH FLOW YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Mineralys Therapeutics, Inc. (MLYS) | $1.97B | N/A | N/A | N/A | N/A |
| Inspire Medical Systems, Inc. (INSP)vs › | $1.98B | 7.94% | 7.39% | 3.49% | 2.93% |
| AxoGen, Inc. (AXGN)vs › | $1.96B | 0.47% | 0.48% | 0.57% | 0.57% |
| Aurinia Pharmaceuticals Inc. (AUPH)vs › | $2.02B | 8.62% | 6.71% | 5.45% | 5.45% |
| Establishment Labs Holdings Inc. (ESTA)vs › | $1.91B | N/A | N/A | N/A | N/A |
| Progyny, Inc. (PGNY)vs › | $2.04B | 12.11% | 10.56% | 8.92% | 5.93% |
| BioCryst Pharmaceuticals, Inc. (BCRX)vs › | $2.04B | 17.62% | 10.04% | 8.73% | 8.73% |
| Immunome, Inc. (IMNM)vs › | $1.90B | N/A | 2.90% | 2.90% | 2.90% |
| Agios Pharmaceuticals, Inc. (AGIO)vs › | $1.90B | N/A | 3.33% | 3.33% | 3.33% |
| Fortrea Holdings Inc. (FTRE)vs › | $2.05B | 8.90% | 8.55% | 14.04% | 13.42% |
OCF Yield = TTM Operating Cash Flow / Market Cap
Operating cash flow yield is the inverse of P/OCF, expressing trailing operating cash flow as a percentage of price. It sits between earnings yield (before non-cash accrual effects) and FCF yield (before capital expenditure).
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
